Press Releases

Jun 11, 2025
COVID-19,Seasonal influenza

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

May 29, 2025
Corporate and finance

Novavax to Participate in Upcoming Investor Conferences

May 19, 2025
COVID-19

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

May 8, 2025
Corporate and finance

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

May 7, 2025
Corporate and finance

Novavax to Participate in BofA Securities 2025 Health Care Conference

May 5, 2025
Corporate and finance

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

May 1, 2025

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 29, 2025
Corporate and finance

Novavax Appoints Charles Newton to Board of Directors

Apr 28, 2025
Statement
COVID-19

Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine

Apr 23, 2025
Statement
COVID-19

Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine

Showper page